Orion Corp New B Shs (ORINF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to Orion's earnings conference call and webcast for the financial period of January-March 2025. My name is Tuukka Hirvonen. I'm the head of IR here at Orion. In a few moments, as you know, we will start this event with CEO Liisa Hurme's presentation, after which you will have the possibility to ask questions from her and also from our CFO, Mr. René Lindell. We will be first taking questions through the conference call lines, and then you also have the possibility to send in your questions through the webcast question form. We kindly ask you to present the company or organization you are representing before asking your question. And just before Letting Liisa step in. Just a reminder about the disclaimer regarding forward-looking statements. And with this, it's my pleasure to hand over to Liisa. Thank you, Tuukka. And good afternoon on my behalf as well. And welcome to Orion Q1 2025 webcast. I'll start with some highlights from our first quarter. I'm happy to tell that all our four businesses created growth, and the fifth one, Fermion, didn't grow, but I will explain a bit about that later on. Also, our geographic expansion and R&D capabilities program is progressing, and we have opened an R&D site in Cambridge. in purpose of strengthening our pharmaceutical development for biologics. Also, there is a new key project in our clinical pipeline. This phase three is on levosimendone for a pulmonary hypertension in certain specific patient segments. And this phase three is carried out by TENAX Therapeutics in United States. On financials, the quarter one was excellent. Net sales grew 15% and our operating profit grew 39%. And also operating profit margin improved from last year's quarter one. Cash flow decreased to some exte...